[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vasculitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vasculitis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,47,77,102,123,152,177,210,232,250,286,312,350,383,410,442,465,532,555,580,603,628,731],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644154","ocular-manifestations-of-granulomatosis-with-polyangiitis-100644154",false,"NCT07664709","Ocular Manifestations of Granulomatosis With Polyangiitis.","Inclusion Criteria:\n\nANCA positive vasculitis age 18- no limit patients with onset od the disease and patients already under treatment\n\n\\-\n\nExclusion Criteria:\n\n* no consent for ophthalmic examination\n* inability to udergo ophthalmic examination","ALL","18 Years",{"count":18,"type":19},70,"ESTIMATED","1 Day","OBSERVATIONAL","The current state of knowledge on ANCA-associated vasculitis (AAV) indicates that it is a group of autoimmune diseases in which small blood vessels in various organs are affected. Disease entities included in this group are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome).\n\nThese are rare diseases, with an incidence in Europe of approximately 20-25 cases per million people per year. There is a slight predominance among men, and the risk of developing the disease increases with age.\n\nANCA antibodies play a role in the pathogenesis of the disease, and inflammation within small vessels leads to damage of the vessel walls, resulting either in rupture or occlusion of the vessel lumen. Consequently, vital organs such as the kidneys, lungs, heart, nervous system, upper respiratory tract, gastrointestinal tract, and eyes may be affected.\n\nIf the disease is not diagnosed, untreated, or treated improperly, it can lead to irreversible failure of these organs and even death. Despite appropriate treatment, AAV diseases tend to relapse; therefore, therapy consists of two phases: induction therapy and maintenance therapy.\n\nCurrent EULAR\u002FEDTA guidelines for induction treatment of AAV recommend the use of cyclophosphamide (CYC) or rituximab (RTX) in combination with glucocorticosteroids in cases of severe disease. If remission is achieved after induction therapy, maintenance treatment should be initiated with drugs such as azathioprine, mycophenolate mofetil, methotrexate, or rituximab, combined with a low dose of glucocorticosteroids. Maintenance therapy should last no less than two years.\n\nThe study will focus on ophthalmological evaluation of patients diagnosed with ANCA-associated vasculitis. In this disease, all structures of the eye may be involved. The most common ocular manifestations include scleritis, keratitis, proptosis, inflammation of orbital tissues, nasolacrimal duct obstruction, and orbital involvement leading to proptosis, double vision, and restricted eye movement.\n\nUntil recently, the disease was often fatal. However, advances in diagnostics and current pharmacological treatment options, combined with appropriately aggressive immunosuppressive therapy, have significantly improved survival, enhanced patients' quality of life, and reduced mortality. Early diagnosis and prompt initiation of appropriate therapy are crucial.",[24,25,26,27],"GPA","Vasculitis","Microscopic Polyangiitis (MPA)","Churg-Strauss Syndrome (CSS)",[29,30,31,32,33],"ocular symptoms","octa","ocular manifestations","scleritis GPA","gpa ocular involvement","RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":38},"2024-03-01",{"date":42,"type":19},"2026-12-31",{"name":44,"class":45},"Military Institute od Medicine National Research Institute","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100540804","phase-3-study-to-evaluate-avacopan-in-combination-with-a-rituximab-or-cyclophosphamide-containing-regimen-in-children-from-6-years-to--18-years-of-age-with-aav-100540804","NCT06321601","Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to \u003C 18 Years of Age With AAV.","A Phase 3, Open-label, Uncontrolled Single-arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Avacopan in Combination With a Rituximab or a Cyclophosphamide-containing Regimen in Children From 6 Years to \u003C 18 Years of Age With Active ANCA-associated Vasculitis (AAV)","Inclusion Criteria:\n\n* Male and female children and adolescents from 6 to \\\u003C 18 years old of age.\n* Clinical diagnosis of Granulomatosis with Polyangiitis (GPA) or microscopic polyangiitis (MPA), consistent with Chapel-Hill Consensus Conference definitions (Jennette et al, 2013).\n* Positive anti-PR3(Anti-Proteinase 3) or anti-MPO(Anti-Myeloperoxidase) antibody documented at Screening or historically. Historical positivity is acceptable (even if Screening is negative) if supported by verifiable lab source documentation obtained during AAV diagnosis or disease course; use the most recent positive result.\n* At least 1 PVAS major item, at least 3 PVAS nonmajor items, or atleast the 2 renal items of proteinuria and hematuria.\n* Estimated glomerular filtration rate (eGFR) of ≥ 15 mL\u002Fminute\u002F1.73 m\\^2 at screening and day 1.\n* Participants must have a bodyweight of ≥ 15 kg at day 1.\n\nExclusion Criteria:\n\n* Any other known multisystem autoimmune disease including and not limited to eosinophilic granulomatosis with polyangiitis (EGPA, previously, Churg-Strauss disease), systemic lupus erythematosus, IgA vasculitis \u002F Henoch-Schönlein, Purpura, rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane disease, or cryoglobulinemic vasculitis.\n* Renal replacement therapy \u002F plasmapheresis: subjects will be excluded who received, require, or initiate CRRT (continuous renal replacement therapy), hemodialysis, any renal dialysis, or plasmapheresis within 14 days prior to Screening or between Screening and Day 1.\n* History of kidney transplantation or is anticipated to require renal transplantation during the study.\n* Alveolar hemorrhage requiring invasive pulmonary ventilation support anticipated to last beyond the screening period of the study.\n* Any medical condition requiring, or expected to require, ongoing treatment with immunosuppressive, therapy (including systemic glucocorticoids) for a non-AAV indication that in the judgment of the investigator, could confound study assessments or interpretation of study results.\n* Female subjects of childbearing potential must have a negative highly sensitive serum pregnancy test at Screening and a negative sensitive urine pregnancy test, on day 1, with results confirmed prior to the first administration of investigational product.\n* Known hypersensitivity or contraindication to avacopan, its excipients, or to any investigational product or required concomitant medication used in this study.\n* Subject likely to not be available to complete all protocol-required study visits or procedures, and\u002For to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the subject and investigator's knowledge.\n* History or evidence of any other clinically significant disorder, condition, or disease (other than those specified above) that, in the investigator's judgment, would pose an unacceptable risk to subject safety, or interfere with study assessments or completion. The investigator may consult the Amgen medical monitor as needed. The rationale for exclusion and any consultation must be documented in the subject's source record.","6 Years","17 Years",{"count":57,"type":19},20,"INTERVENTIONAL",[60],"PHASE3","The main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.",[25],[64,65,66],"Pediatric","Avacopan","Tavneos®",{"date":68,"type":38},"2026-06-18",{"date":70,"type":38},"2024-10-22",{"date":72,"type":19},"2028-09-26",{"name":74,"class":75},"Amgen","INDUSTRY",34,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":58,"phases":85,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":46},"100258086","phase-1-infliximab-therapy-for-dolichoectactic-vertebrobasilar-aneurysms-100258086","NCT02638701","Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms","Inclusion Criteria:\n\n1. Vertebral and\u002For basilar artery dolichoectactic aneurysm not amenable to microsurgical or endovascular treatment.\n2. Age greater than 18 years at time of first study drug administration.\n\nExclusion Criteria:\n\n1. Use of an anti-TNF or other biologic medication (Including but not limited to abatacept, rituximab, or tocilizumab) within the previous 12 months.\n2. The following laboratory parameters at the Screening visit: Neutropenia (absolute neutrophil count \\\u003C 1,500\u002Fmicroliter; Thrombocytopenia (platelets \\\u003C 100,000\u002F • Anemia (hemoglobin \\\u003C 8 g\u002FdL); Greater than or equal to 3 times the upper limit of normal (ULN) for either of the following liver function tests (LFTs): aspartate transaminase (AST) or alanine transaminase (ALT); Renal insufficiency (serum creatinine\\> 2.0 mg\u002FdL)\n3. Purified protein derivative (PPD) test of \\> 5 mm induration regardless of prior BacilleCalmette Guerin vaccine administration or positive QuantiFERON®-TB Gold In-Tube Test (QFT-G\\_IT) without documentation of completed treatment or evidence of ongoing treatment of latent tuberculosis (TB) for 30 days. Subjects with active TB infection are excluded.\n4. History of positive PPD, positive QuantiFERON®-TB Gold In-Tube Test (QFT-G\\_IT), or chest x-ray findings indicative of prior TB infection, without documentation of either treatment for TB infection or chemoprophylaxis for TB exposure\n5. Presence of open leg ulcers\n6. Chronic or persistent infection including but not limited to human immunodeficiency virus \\[HIV\\], untreated hepatitis B, listeriosis, TB, or other opportunistic infection). Patients with hepatitis C but without evidence of cirrhosis or significant hepatic dysfunction will be considered for inclusion on a case-by-case basis as will patients with chronic hepatitis B on anti-viral therapy.\n7. Active infection or severe infections requiring hospitalization or treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to randomization, or oral antibiotics, oral antivirals, or oral antifungals within 14 days prior to randomization\n8. Receipt of a live vaccine within 4 weeks prior to randomization\n9. History of malignancy within the past 5 years other than treated localized carcinoma in situ of the cervix or adequately treated non-metastatic squamous or basal cell skin carcinoma\n10. Any medical condition, which, in the opinion of the investigator, would put the subject at risk by participation in the protocol\n11. Women of childbearing potential who are sexually active and who do not agree to practice one of the following methods of contraception during the duration of the study: condoms, sponge, foams, jellies, diaphragm or intrauterine device; oral or parenteral contraceptives for 2 months prior to study product administration; a vasectomized partner; abstinence.\n12. Pregnant (all women of childbearing potential must have a negative serum pregnancy test) or breastfeeding\n13. Any investigational agent within the earlier of 4 weeks or 5 half-lives prior to randomization\n14. History of drug or alcohol abuse within 6 months prior to randomization\n15. Known allergy or hypersensitivity to any study products\n16. Any psychiatric disorder that prevents the subject from providing informed consent\n17. Inability or unwillingness to follow the protocol.\n18. Unable to undergo MR imaging.",{"count":84,"type":19},8,[86,87],"PHASE1","PHASE2","Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and\u002For brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms",[90,91,25,92],"Aneurysm","Stroke","Tumor Necrosis Factor-alpha","2026-06-08",{"date":95,"type":38},"2026-06-11",{"date":97,"type":38},"2024-10-01",{"date":99,"type":19},"2028-12",{"name":101,"class":45},"University of California, San Francisco",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":109,"targetDuration":111,"studyType":21,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":46},"100638537","systemic-vasculitis-prognosis-and-outcome-100638537","NCT07586137","SysteMic vAsculitis pRognosis and ouTcome","SMART","Inclusion Criteria:\n\n* Willing and able to give informed consent\n* clinical suspicion or a confirmed diagnosis of Systemic Vasculitis\n\nExclusion Criteria:\n\n* Inability to give informed consent",{"count":110,"type":19},300,"10 Years","This will be a pragmatic programme of research, consecutively recruiting all-comers who have been referred to secondary care for assessment of suspected Systemic Vasculitis (SV) into a longitudinal inception cohort. For patients with a pre-existing diagnosis, data on the disease onset will be collected retrospectively. All patients followed prospectively from the time of inclusion into the study will be followed at intervals corresponding to the recommended standard of care. We will invite participants to consent to the whole programme of research in order to allow their samples, as well as their data, to be used for in multiple related projects that have the same common aim. In this long-term inception cohort we will collect data on clinical features, prognostic factors and outcomes of patients diagnosed with a SV over the course of 10 years. We will examine the role of clinical features, imaging and biomarkers in the characterisation of the disease with a particular focus on risk stratification. This will be closely integrated with the other objectives of the study: analysing clinical features, imaging characteristics, outcomes, rates and predictors of relapses and remission, in order to obtain a prognostic stratification of the patients and to capture a cohort of patients at high risk of relapse and poor outcome who could inform on the potential use of more intensive treatment strategies to be assessed in future studies.\n\nThe SMART programme will be guided by three main overarching themes:\n\n1. \"Theme 1\": The identification of risk factors associated with poor outcome, relapse and failure to achieve remission\n2. \"Theme 2\": The assessment of different tools to assess risk factors (imaging, biomarkers, clinical features)\n3. \"Theme 3\": The analysis of cohorts of SV patients in observational studies The overarching aims of the study will be overlapping throughout the different investigations outlined in the following paragraphs analyzing: outcomes (including treatment-derived damage), monitoring and relapse, and remission in SV.\n\nWe aim to follow patients up over a total of 10 years, in order to provide the richest and most complete set of data that has ever been collected for this patient group.",[25],"2026-05-08",{"date":116,"type":38},"2026-05-14",{"date":118,"type":38},"2022-02-08",{"date":120,"type":19},"2030-06-15",{"name":122,"class":45},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":15,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":132,"conditions":133,"keywords":139,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":46},"100614362","the-rheumsafer-study-improving-medication-appropriateness-in-people-with-rheumatic-conditions-100614362","NCT07278609","The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions","Inclusion Criteria:\n\n* Aged ≥60\n* Followed by a rheumatologist at MUHC for an inflammatory arthritis (such as rheumatoid arthritis, psoriatic arthritis, spondyloarthritis), a systemic autoimmune rheumatic disease (such as systemic lupus erythematosus, inflammatory myositis, systemic sclerosis, antiphospholipid antibody syndrome, Sjogren syndrome, systemic vasculitis), or another chronic musculoskeletal or rheumatic condition (such as crystal arthritis and osteoarthritis)\n* Currently taking ≥5 regular medications and ≥1 PIM\n* Anticipated ongoing clinical follow-up in rheumatology at an interval of every 3-9 months\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Acute life-threatening illness or life expectancy \\\u003C12 months","60 Years",{"count":131,"type":19},100,"The goal of this prospective observational quality improvement study is to determine if a physician tool, MedSafer, combined with educational brochures for patients, can help to reduce the use of 'potentially inappropriate medications' (PIMs) in adults aged 60 and over with rheumatic conditions and polypharmacy (taking 5 or more regular medications).\n\nResearchers will follow participants during usual rheumatic disease care. They will compare the rate of PIM deprescribing (stopping medications or reducing the dose) before and after the introduction of the following interventions:\n\n* MedSafer reports provided to treating physicians\n* EMPOWER consumer brochures provided to participants\n\nParticipants will complete 4 study visits over 18-20 months during which researchers will collect information on medication changes, serious adverse events (emergency visits or hospitalizations), and quality of life.",[134,135,136,25,137,138],"Rheumatic Diseases","Inflammatory Arthritis","Systemic Lupus Erthematosus (SLE)","Muskuloskeletal Diseases","Systemic Autoimmune Diseases",[140,141,134,142],"Deprescribing","Potentially inappropriate medications","Polypharmacy","2026-04-27",{"date":145,"type":38},"2026-05-01",{"date":147,"type":38},"2025-10-29",{"date":149,"type":19},"2028-06-30",{"name":151,"class":45},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":46},"100440187","evaluation-of-high-dose-prednisolone-pharmacokinetics-in-the-acute-and-chronic-setting-100440187","NCT05012033","Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting","EHD-Pred PK","Inclusion Criteria:\n\n* Aged 18 - 75 years\n* Male or female\n* Participants who are otherwise healthy enough to participate, as determined by pre-study medical history\n* Participants who are able and willing to give written informed consent to participate in the study\n* Group A only: Patients requiring acute (\\\u003C5 days) high dose (minimum 30mg) oral prednisolone therapy for antiinflammatory purposes in either an inpatient or outpatient setting.\n* Group B only: Minimum of 1 month duration of high dose prednisolone (\\>30mg) if in the chronic use group.\n* Group C only: Patients started on high dose methylprednisolone (\\>3 day course) or prolonged courses of dexamethasone.\n\nExclusion Criteria:\n\n* Participants with a diagnosis of Type 1 or Type 2 diabetes mellitus.\n* Unable to give informed consent.\n* Taking supplements or herbal medications that the participant is unwilling or unable to stop prior to and during the study period e.g. St John's Wort (may decrease prednisolone levels), Cat's claw, Echinacea (immunomodulatory properties).\n* Currently taking medications that alter CYP3A4 metabolism of glucocorticoids that the participant is unwilling or unable to stop prior to and during the study period e.g. phenytoin, phenobarbital, rifampicin, rifabutin, carbamazepine, primidone, aminogluethimide, itraconazole, ketoconazole, ciclosporin or ritonavir.\n* Pregnancy. Females of child-bearing age will be asked to provide a urine sample for a pregnancy test at each visit.\n* History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or compromise the safety of the participant.","75 Years",{"count":161,"type":19},120,"This is a pilot study to investigate serum prednisolone profiles in:\n\n* Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting.\n* Patients stepping up from or down to prednisolone therapy in association with a course of high dose methyl-prednisolone or dexamethasone.\n\nThe study will comprise 3 groups, including those started on high doses of prednisolone acutely in an inpatient or outpatient setting, participants on chronically high doses, and those receiving a several week course of high dose methylprednisolone or dexamethasone.\n\nThe study aims to measure prednisolone levels at a number of time points to investigate serum profile differences in those receiving prednisolone acutely compared with longer term steroid use. Further samples will be taken to characterise additional metabolic changes.",[164,25,165,166,167],"Thyroid Eye Disease","COPD Exacerbation Acute","Asthma","Inflammatory Disease","2026-03-24",{"date":170,"type":38},"2026-03-27",{"date":172,"type":38},"2023-04-12",{"date":174,"type":19},"2030-12-31",{"name":176,"class":45},"Imperial College London",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":188,"conditions":189,"keywords":194,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":46},"100458576","clinico-biological-collection-to-investigate-the-physiopathology-of-systemic-autoimmune-diseases-100458576","NCT05251415","Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases","Constitution of a Collection of Biological Samples With the Aim of Carrying Out Clinico-biological and Pathophysiological Investigations of Systemic Autoimmune Diseases","ESSAi","Inclusion Criteria:\n\n* Patients with rare systemic autoimmune diseases (lupus, scleroderma, myositis for example),\n* Patients with atypical presentations of documented or probable systemic autoimmune diseases,\n* Patients receiving, or likely to receive new, innovative therapies (new molecule on the market, gene therapy, cell therapy, etc.).\n\nExclusion Criteria:\n\n* Known anemia and hemoglobin \\\u003C10 g \u002F dl\n* Patients under protective supervision (guardianship, curators)\n* Pregnant or breastfeeding woman","99 Years",{"count":187,"type":19},3000,"The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies",[190,191,192,25,193],"Lupus Erythematosus","Scleroderma","Myositis","Inflammatory Bowel Diseases",[195,196,197,198,199,193,200],"systemic autoimmune diseases","scleroderma","lupus","myositis","vasculitis","new therapies","2026-03-16",{"date":203,"type":38},"2026-03-17",{"date":205,"type":38},"2022-04-04",{"date":207,"type":19},"2032-04-04",{"name":209,"class":45},"University Hospital, Toulouse",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":229,"locationsCount":231},"100495684","longitudinal-study-for-central-nervous-system-vasculitis-100495684","NCT05734404","Longitudinal Study for Central Nervous System Vasculitis","Inclusion Criteria:\n\ni. Diagnostic criteria for CNSV\n\n1. The presence of an acquired and otherwise unexplained neurologic deficit\n2. The presence of either classic angiographic or histopathologic features of angiitis in the CNS\n3. No evidence of systemic vasculitis or any condition that could cause the angiographic or pathologic features\n\nii. ≥18 years of age\n\nExclusion Criteria:\n\ni. Unwilling to sign informed consent.",{"count":217,"type":19},40,"Primary central nervous system vasculitis (CNSV) is a potentially fatal, single-organ vasculitis that often involves a spectrum of neurologic complications, including strokes, cognitive and speech impairment, visual loss, dementia, and encephalopathy. The purpose of this study is to establish a research cohort to investigate the disease process, treatments, and patient outcomes in CNSV.",[220,221,222,25],"Central Nervous System Vasculitis","CNS Vasculitis","CNSV","2026-01-21",{"date":225,"type":38},"2026-01-23",{"date":227,"type":38},"2023-03-01",{"date":174,"type":19},{"name":230,"class":45},"University of Pennsylvania",6,{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":46},"100433085","longitudinal-study-for-relapsing-polychondritis-100433085","NCT04919538","Longitudinal Study for Relapsing Polychondritis","Inclusion Criteria:\n\n* 1\\. Any subject considered to have a diagnosis of relapsing polychondritis according to the investigator.\n\nExclusion Criteria:\n\n* 1\\. Inability to provide consent, or in the case of minors, assent.",{"count":131,"type":19},"Relapsing polychondritis (RP) is a rare systemic inflammatory disease characterized by recurrent inflammation of cartilage including ears, nose, tracheobronchial tree, chest wall and joints. Less commonly, it can cause inflammation of eyes, vasculature, nervous system, skin and inner ear. The purpose of this study is to study the pathogenesis of RP.",[241,25],"Relapsing Polychondritis",[243],"RP",{"date":225,"type":38},{"date":246,"type":38},"2021-02-26",{"date":248,"type":19},"2030-01",{"name":230,"class":45},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":15,"minAge":257,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":260,"conditions":261,"keywords":270,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":283,"locationsCount":285},"100286105","clinical-transcriptomics-in-systemic-vasculitis-cutis-100286105","NCT03004326","Clinical Transcriptomics in Systemic Vasculitis (CUTIS)","CUTIS","Inclusion Criteria:\n\n* Have a cutaneous lesion (purpuric macules, palpable purpura, retiform purpura, nodules, ulcers, or urticarial) believed to be related to active vasculitis\n* Have a suspected or confirmed diagnosis of:\n\n  * Cryoglobulinemic vasculitis (CV)\n  * Drug-induced vasculitis\n  * Eosinophilic granulomatosis with polyangiitis (EGPA)\n  * IgA vasculitis\n  * Isolated cutaneous vasculitis\n  * Granulomatosis with polyangiitis (GPA)\n  * Microscopic polyangiitis (MPA)\n  * Polyarteritis nodosa (PAN)\n  * Urticarial vasculitis\n* Be willing and able to provide written informed consent (or assent for those under\n\nExclusion Criteria:\n\n* You are less than five years old\n* Considered not to be a candidate for a biopsy or have a higher risk of developing an infection, bleeding, etc., from the biopsy, or a doctor believes that the risks for you participating in this study do not outweigh the potential benefit of learning information from your biopsy\n* You have a neutrophil count (type of white blood cell) less than 1500\u002Fmm3, platelet count less than 50,000\u002Fmm3, or a hemoglobin less than 7 g\u002FdL\n* You have an uncontrolled disease that could prevent you from completing the study procedures\n* You have an active infection at or near the potential biopsy site, have poor circulation, or have bony prominence or other structure that would increase your risk of complications if you participated in this study\n* You are pregnant or nursing\n* You are not able to provide informed consent","5 Years",{"count":259,"type":19},50,"Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.",[262,263,264,265,266,267,26,268,269,25],"Cryoglobulinemic Vasculitis (CV)","Drug-induced Vasculitis","Eosinophilic Granulomatosis With Polyangiitis (EGPA)","IgA Vasculitis","Isolated Cutaneous Vasculitis","Granulomatosis With Polyangiitis (GPA)","Polyarteritis Nodosa (PAN)","Urticarial Vasculitis",[271,272,273,274,24,275,276,277],"DIV","CSS","EGPA","HSP","MPA","PAN","Wegeners",{"date":279,"type":38},"2026-01-22",{"date":281,"type":38},"2017-01",{"date":99,"type":19},{"name":284,"class":45},"Peter Merkel",10,{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":294,"minAge":16,"maxAge":295,"enrollmentInfo":296,"targetDuration":297,"studyType":21,"phases":4,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":46},"100254637","vasculitis-pregnancy-registry-100254637","NCT02593565","Vasculitis Pregnancy Registry","The Vasculitis Pregnancy Registry (V-PREG)","V-PREG","Inclusion Criteria:\n\n1. Women 18 years of age or older with one of the following diseases may take part in the study:\n\n   * Behçet's disease;\n   * Central nervous system (CNS) vasculitis;\n   * Cryoglobulinemic vasculitis (Cryoglobulinemia);\n   * Eosinophilic granulomatosis with polyangiitis (also called Churg-Strauss Syndrome);\n   * Giant Cell (Temporal) Arteritis (GCA);\n   * Granulomatosis with polyangiitis (also called Wegener's);\n   * IgA vasculitis (Henoch-Schoenlein purpura);\n   * Microscopic polyangiitis (MPA);\n   * Polyarteritis nodosa (PAN);\n   * Takayasu's arteritis (TAK);\n   * Urticarial vasculitis;\n   * Other\u002FSuspected Diagnosis.\n2. Women must be pregnant (self-report) at the time of enrollment into the registry.\n\nExclusion Criteria:\n\n1. Non-English speaking, with the exception of people who speak Spanish, Portuguese, Italian, or Turkish.\n2. Unable to provide consent.","FEMALE","50 Years",{"count":131,"type":19},"12 Months","The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several online surveys to assess\n\n1. each woman's vasculitis severity and pregnancy-related experiences, and\n2. pregnancy outcomes.",[25,300,221,301,264,27,267,302,265,303,26,268,304,269,305],"Behcet's Disease","Cryoglobulinemic Vasculitis","Wegener's Granulomatosis","Henoch-Schoenlein Purpura (HSP)","Takayasu Arteritis (TAK)","Systemic Vasculitis",{"date":225,"type":38},{"date":308,"type":4},"2015-11",{"date":310,"type":19},"2027-12",{"name":230,"class":45},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":320,"conditions":321,"keywords":336,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":46},"100616152","generative-ai-impact-on-rheumatoid-arthritis-complications-diagnosis-100616152","NCT07301892","Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis","Impact of Generative Artificial Intelligence on Diagnosing Rheumatoid Arthritis Complications","Inclusion Criteria:\n\n* Patients with an initial diagnosis of rheumatoid arthritis (RA).\n* All real-world RA inpatients admitted to our department.\n* Admission occurring within the real-world data study period.\n\nExclusion Criteria:\n\n* Patients subsequently confirmed not to have RA during the study.",{"count":131,"type":19},"Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.",[322,323,324,325,326,327,328,329,330,331,25,332,333,334,335],"Rheumatoid Arthritis (RA","Osteoporosis","Osteoarthritis","Interstitial Lung Disease","Thyroid Diseases","Cardiovascular Diseases","Pulmonary Complications","Sjogren's Syndrome","Liver Disorders","Renal Lesions","Amyloidosis","Peripheral Neuropathy","Thrombosis","RA Complications",[337,338,339,340],"Rheumatoid Arthritis","generative AI","large language model","Rheumatoid arthritis complications","2025-12-22",{"date":343,"type":38},"2025-12-24",{"date":345,"type":38},"2025-10-01",{"date":347,"type":19},"2026-06",{"name":349,"class":45},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":46},"100487581","vascular-lab-resource-vlr-biorepository-100487581","NCT05628948","Vascular Lab Resource (VLR) Biorepository","Vascular Lab Resource (VLR) Biorepository Study","Inclusion Criteria:\n\n1. 18 years or older\n2. Subjects capable of providing informed consent document\n3. Subjects with diagnosed with or at risk for cardiovascular and metabolic diseases\n\nExclusion Criteria:\n\n1. Known life expectancy of ≤ 6 months at the time of enrollment\n2. Known current pregnancy\n3. Severe Anemia (last documented hemoglobin \\\u003C 7.0 g\u002FdL)",{"count":358,"type":19},500,"This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular disease in the Vascular Lab and will leverage this valuable asset to the fullest extent to allow for interdepartmental collaboration.",[327,361,362,363,364,365,334,366,367,368,25,369,370,371,372,373],"Metabolic Disease","Peripheral Artery Disease","Carotid Disease","Aneurysmal Disease","Venous Disease","Lymphedema","Lipedema","Non-Atherosclerotic Chronic Arterial Occlusive Disease","Fibromuscular Dysplasia","Arterial Dissection","May-Thurner Syndrome","Thoracic Outlet Syndrome","Vasospasm","2025-12-15",{"date":376,"type":38},"2025-12-19",{"date":378,"type":38},"2019-11-14",{"date":380,"type":19},"2031-06-30",{"name":382,"class":45},"The Cleveland Clinic",{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":391,"conditions":392,"keywords":396,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":46},"100569774","memri-and-kidney-disease-100569774","NCT06698614","MEMRI and Kidney Disease","Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Patients With Kidney Disease","Inclusion Criteria:\n\nAll subjects to be entered must:\n\nBe able to provide written informed consent after having received oral and written information about the study.\n\n\\>18 years of age Availability to complete study visits If female, be non-pregnant as evidenced by a negative pregnancy test or be post-menopausal or surgically sterile.\n\nAdditionally, cohort specific inclusion criteria are as follows:\n\nCohort 1; Acute kidney injury-\n\nA diagnosis of AKI will be made based on the following criteria (based on the definition used in the Kidney Precision Medicine Project www.kpmp.org):\n\nPrevious (within 3 years) eGFR \\>45 ml\u002Fmin\u002F1.73m2 OR no history of kidney disease if no blood results available AND Elevated creatinine \\>1.5x previous result OR \\>150 μmol\u002FL if no previous value AND Increasing creatinine within 48 hours OR requirement for dialysis.\n\nCohort 2; Chronic kidney disease- Stable CKD for at least 6 months (monitored by eGFR), matched to AKI cohort at follow up based on renal function.\n\nCohort 3: Matched controls- Matched to AKI cohort participants at baseline for age, sex, cardiovascular disease risk and cardiovascular medication.\n\nCohort 4; Vasculitis- A new diagnosis of vasculitis or an existing diagnosis with relapsing disease, and kidney involvement.\n\nCohort 5; Kidney transplantation- Has kidney failure and has received a kidney transplant in the preceding 1 month.\n\nCohort 6: Kidney transplant rejection- Biopsy proven episode of transplant rejection.\n\nExclusion Criteria:\n\nThe following criteria apply to all patients:\n\n1. Unable to give informed consent.\n2. Have any contraindications to standard MRI safety criteria, including implanted devices.\n3. Subjects under the age of 18 years old.\n4. Pregnancy\u002Fpositive pregnancy test.\n5. Current breastfeeding.\n6. Have a diagnosis of kidney disease due to polycystic kidney disease.\n7. Patients in critical care or on surgical wards will be excluded.\n8. Patients taking calcium channel antagonists or digoxin.\n\nAdditionally, cohort specific exclusion criteria are as follow:\n\nCohort 1- Excluded if they have a diagnosis of diabetes. Cohort 2- Excluded if receiving dialysis or those with a functional kidney transplant, multi-system disorders (e.g., systemic vasculitis), or any patients receiving immunosuppression.",{"count":161,"type":19},"Acute kidney injury (AKI) is common and costly.1 Although patients who suffer an episode of AKI may recover, many will go on to develop cardiovascular disease and chronic kidney disease (CKD). Cardiovascular disease is an important complication of AKI.2 Similar to AKI, CKD and kidney transplantation and kidney donation associations with cardiovascular disease.1 The risk of cardiovascular disease complications is also increased in patients with inflammatory diseases that affect the kidneys, such as vasculitis.\n\nCurrently, there are no reliable biomarkers that will identify those patients with kidney disease that will go on to develop cardiovascular disease. This study will explore the potential of manganese-enhanced magnetic resonance imaging (MEMRI) to act as a biomarker of AKI and its cardiovascular and renal complications. An analogue of calcium, manganese is readily taken-up into viable cells where it increases T1 relaxivity. Preliminary data show rapid manganese uptake in the heart and kidneys of healthy subjects.\n\nThe investigators propose to use MEMRI to demonstrate differences in renal and myocardial calcium handling in patients with acute insults (such as AKI, transplant rejection, donation or episodes of rejection or new vasculitis presentations) or improvements (such as transplantation). The investigators will also investigate whether these abnormalities reverse in those whose injury resolves or persist in those who clearly develop CKD, or who are at risk of future cardiovascular disease and CKD.",[393,394,25,395],"Acute Kidney Injury","Kidney Transplant","Chronic Kidney Disease(CKD)",[397,398,399,400],"manganese enhanced magnetic resonance imaging","kidney disease","MEMRI","Manganese enhanced MRI","2025-12-01",{"date":403,"type":38},"2025-12-08",{"date":405,"type":38},"2024-11-07",{"date":407,"type":19},"2029-11-07",{"name":409,"class":45},"University of Edinburgh",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":417,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":419,"conditions":420,"keywords":430,"overallStatus":433,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":438,"leadSponsor":440,"locationsCount":4},"100607417","mass-spectrometry-based-immune-profiling-in-autoimmune-diseases-100607417","NCT07188285","Mass Spectrometry-based Immune Profiling in Autoimmune Diseases","Mass Spectrometry-based Immune Profiling in Peripheral Blood of Autoimmune Diseases","Inclusion Criteria:\n\n1. Male or female, and aged 18-70 at the time of screening interview (inclusive).\n2. The diagnosis of each disease meets the following standards - Systemic lupus erythematosus: 1997 ACR lupus classification standard\n\n   * Behcet's disease: 2014 ICBD Behcet's disease classification standard\n   * ANCA-associated vasculitis: 1990 American College of Rheumatology Classification Standard\n   * Rheumatoid arthritis: 1987 ARA classification standard\n   * Ankylosing spondylitis: new york standard revised in 1984\n   * Sjogren's syndrome: 2016 ACR\u002FEULAR Sjogren's syndrome classification standard\n   * Inflammatory myopathy: Bohan recommended criteria in 1977\n   * Systemic sclerosis: SSc standard formulated by American Rheumatology Association in 1980.\n   * Psoriatic arthritis: CASPAR standard in 2006\n   * Gouty arthritis: 1997 ACR gout classification standard\n3. Disease activity status, each disease should meet the disease activity index;\n4. Glucocorticoid (≤1mg\u002Fkg\u002Fd prednisone or other hormones with equivalent dose) was used before joining the group, and DMARDs (such as methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, leflunomide, cyclosporine, etc.) were allowed;\n5. When participating in the trial, the patient must be informed in writing and hope that the patient can abide by the requirements of the research follow-up plan and other protocols.\n\n   Exclusion Criteria:\n\n1\\. Use IVIg or cyclophosphamide within 1.2 months, use other biological agents (infliximab, adalimumab, etanercept, anakinra, etc.) within 3 months, and use rituximab within 6 months; 2.1 months after receiving high-dose glucocorticoid (\\> 1 mg\u002Fkg\u002Fd). 3. Serious complications: including heart failure (≥ NYHA III), renal insufficiency (creatinine clearance rate ≤30 ml\u002Fmin) and hepatic insufficiency (serum ALT or AST is greater than three times the normal upper limit, or total bilirubin is greater than the normal upper limit).\n\n4\\. Other serious, progressive or uncontrollable hematological, gastrointestinal, endocrine, lung, heart, nerve or brain diseases (including demyelinating diseases, such as multiple sclerosis).\n\n5\\. Suffering from serious infection (including but not limited to hepatitis, pneumonia, bacteremia, pyelonephritis, EB virus, tuberculosis infection), or being hospitalized due to infection, or using intravenous antibiotics to treat infection 2 months before the first dose of treatment.\n\n6\\. Chest imaging showed abnormalities of malignant tumor or current active infection (including tuberculosis) within 3 months before enrollment.\n\n7\\. Infected with HIV(HIV antibody positive serology) or hepatitis C (Hep C antibody positive serology). If the serum is positive, it is recommended to consult a doctor with expertise in treating HIV or hepatitis C virus infection.\n\n8\\. Any known malignant tumor or history of malignant tumor in the past 5 years. 9. Received any vaccination within 3 months before joining the group.",true,{"count":358,"type":19},"Based on mass spectrometry flow method, this study analyzed the typing of new T, B, NK and DC cell subsets in peripheral blood of common autoimmune diseases and their correlation with disease activity, aiming at establishing an early screening and diagnosis model of autoimmune diseases.",[421,422,423,424,25,425,426,324,427,428,429],"Systemic Lupus Erthematosus","Sjogren's Syndrome","Inflammatory Myopathies","Systemic Sclerosis (SSc)","Rheumatoid Arthritis (RA)","Ankylosing Spondylitis","Gouty Arthritis (GA)","Psoriatic Arthritis (PsA)","Healthy Controls",[431,432],"autoimmune diseases","mass spectrometry","NOT_YET_RECRUITING","2025-09-16",{"date":436,"type":38},"2025-09-23",{"date":434,"type":19},{"date":439,"type":19},"2026-09-30",{"name":441,"class":45},"Peking University People's Hospital",{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":452,"conditions":453,"keywords":454,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":46},"100394228","prospective-longitudinal-cohort-study-of-vasculitis-patients-100394228","NCT04413331","Prospective Longitudinal Cohort Study of Vasculitis Patients","Cohort Study of Vasculitis Patients: Longitudinal Study for the Assessment of Presentation, Comorbidities, Management, Outcomes and Damage","VASCO","Inclusion Criteria:\n\n* Adult patients (age over 18 years),\n* Patients with vasculitis, as defined in the Chapel Hill International Nomenclature as revised in 2012,\n* Patients included at an active phase of the disease, either the initial flare or a relapse,\n* Patients who have been informed and have signed the consent\n* Pregnant and breastfeeding women may be included in the study,\n* Affiliated to a social security system (beneficiary or entitled person).\n\nExclusion Criteria:\n\n* Refusal of consent or inability to obtain consent,\n* A patient who is insane or not entitled, for psychiatric reasons or intellectual impairment, to receive information about the protocol and to give informed consent,\n* Patient under guardianship \u002F curators\n* Patient on state medical assistance (AME)\n* Hemoglobin less than 7 g\u002Fdl at the time of sampling,\n* Hemoglobin level less than 9 g\u002Fdl at the time of sampling if the patient has respiratory or cardiovascular disease,\n* Patient weighs less than 18 kg.\n* Parallel participation in an interventional protocol is permitted.",{"count":451,"type":19},670,"VASCO is a prospective observational cohort study which aim to describe the presentation, comorbidities, management, outcomes and damage of vasculitis patients, from the analysis of the clinical, biological and immunological data.",[25],[455],"Prospective vasculitis cohort","2025-09-05",{"date":458,"type":38},"2025-09-12",{"date":460,"type":38},"2020-07-02",{"date":462,"type":19},"2032-07",{"name":464,"class":45},"Assistance Publique - Hôpitaux de Paris",{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":473,"targetDuration":257,"studyType":21,"phases":4,"briefSummary":475,"conditions":476,"keywords":495,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":530,"locationsCount":46},"100230679","a-real-world-registry-of-chronic-wounds-and-ulcers-100230679","NCT02280733","A Real-World Registry of Chronic Wounds and Ulcers","A Longitudinal, Real World, Observational Registry of Chronic Wounds and Ulcers and the Patients Who Have Them","WOUNDJOURNEY","Inclusion Criteria:\n\n* Presence of one or more chronic wounds or ulcers of any etiology\n* Wound or ulcer must be treated at a participating site (which can be a hospital outpatient department, office, mobile practitioner, in the home setting, skilled nursing, etc.)\n* Care must be documented using the purpose-built, wound-specific structured electronic health record (EHR) or electronic data capture (EDC) system\n* All ages, including infants and patients aged 90 years or older (reported in aggregate in accordance with HIPAA de-identification standards)\n* All sexes and gender identities\n* All wound types and severities, including multiple wounds per patient\n\nExclusion Criteria:\n\n-None (the registry includes all eligible patients treated at participating sites without sampling or exclusion criteria)",{"count":474,"type":19},300000,"WOUNDJOURNEY is a longitudinal, real-world, observational registry designed to capture the full clinical course and patient journey associated with chronic wounds and ulcers. Data are collected during routine care from over 1,400 clinicians across the USA and Puerto Rico using a highly structured certified electronic health record (EHR) or electronic data capture (EDC) system. Data are transmitted daily to the U.S. Wound Registry (USWR), a CMS-recognized Qualified Clinical Data Registry (QCDR). The registry captures real-time, research-ready data on patient demographics, comorbidities, wound characteristics, standard-of-care treatments, complications, and advanced therapeutics. It supports robust, fit-for-purpose real-world evidence generation by enabling risk-adjusted outcome analysis, comparative effectiveness research, and quality improvement across diverse sites of care.",[477,478,479,25,480,481,482,483,366,484,485,486,487,488,489,490,491,492,493,494],"Diabetic Foot","Pressure Ulcer","Surgical Wound Dehiscence","Skin Ulcer","Leg Ulcer","Pyoderma","Peripheral Arterial Disease","Surgical Complication","Venous Leg Ulcers (VLUs)","Calciphylaxis","Sickle Cell Ulcer","Pressure Ulcer (PU)","Diabetic Foot Ulcers (DFUs)","Pressure Injury","Arterial Ulcers","Soft Tissue Radionecrosis (STRN)","Traumatic Wounds","Chronic Ulcer",[496,497,498,499,500,501,502,503,478,490,504,505,484,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523],"Qualified Clinical Data Registry","Quality Measures","Clinical Data Research Network","Real world data","chronic wounds","chronic ulcers","Diabetic Foot Ulcer","Venous Leg Ulcer","Arterial Ulcer","Traumatic Wound","Pyoderma Gangrenosum","Advanced Wound Care","Skin Substitutes","CAMPs","CTPs","Negative Pressure Wound Therapy","NPWT","Collagen Dressings","Compression Therapy","Hyperbaric Oxygen Therapy","Wound Debridement","Real-World Evidence","Comparative Effectiveness","Wound Healing","Amputation","Electronic Health Record (EHR)","Debridement","Standard of Care","2025-07-10",{"date":526,"type":38},"2025-07-16",{"date":528,"type":38},"2005-01-01",{"date":248,"type":19},{"name":531,"class":45},"U.S. Wound Registry",{"id":533,"slug":534,"hasResults":11,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":541,"conditions":542,"keywords":545,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":46},"100468711","biomarkers-in-autoimmune-diseases-vasculitis-and-auto-inflammatory-diseases-100468711","NCT05383339","Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases","BIOMAI","Inclusion Criteria:\n\n* Patients of 18 years of age or older\n* Patients with autoimmune systemic disease, systemic vasculitis or autoinflammatory disease, defined by the international criteria in force for each pathology, among the following:\n\n  * Connectivities: lupus, Sjögren syndrome, antiphospholipid syndrome, mixed connectivity and Sharp syndrome, scleroderma, myositis\n  * Vasculitis of large, small and medium vessels: giant cell arteritis, Takayasu arteritis, Behçet disease, ANCA vasculitis, cryoglobulinemic vasculitis, IgA vasculitis (rheumatoid purpura)\n  * Buerger's disease (obliterating thromboangitis)\n  * Granulomatosis and sarcoidosis\n  * Uveitis\n  * Monogenic and polygenic autoinflammatory diseases: family Mediterranean fever, TRAPS, CAPS, chronic atrophic polychondritis, pericarditis\n  * Recurrent fevers and unexplained inflammatory syndromes\n  * Inflammatory amyloidosis\n* Patients affiliated to French social security\n\nExclusion Criteria:\n\n* Vulnerable populations:\n\n  * Persons deprived of liberty by judicial or administrative decision;\n  * Persons receiving psychiatric care without their consent;\n  * Adult subject to a legal protection measure (guardianship, curatorship);\n  * Persons unable to give their consent.",{"count":540,"type":19},2250,"The objective of this work is to identify, in patients with autoimmune diseases, systemic vasculitis and autoinflammatory disease, cytokine and lymphocyte biomarkers of activity of these diseases to identify follow-up biomarkers, in order to personalize the follow-up and the treatments for each patient.\n\nImmunological data will be obtained from biological samples collected as part of the usual patient care pathway (Blood and tissues sampling) The study will take place in the Department of Internal Medicine and Clinical Immunology (DMIIC), that is certified as the National Reference Centre for Rare Systemic Autoimmune Diseases and the National Reference Centre for Inflammatory Autoinflammatory Diseases and Inflammatory Amyloidosis (CEREMAIA). Its objective is to contribute to the advancement of fundamental knowledge in immunology, in particular to develop prognostic biomarkers of the activity of autoimmune diseases, systemic vasculitis and autoinflammatory diseases by using blood tests.",[543,25,544],"Autoimmune Diseases","Autoinflammatory Disease",[543,25,544,546],"disease activity biomarkers cytokine and lymphocyte profile","2025-06-30",{"date":549,"type":38},"2025-07-03",{"date":551,"type":38},"2022-11-29",{"date":553,"type":19},"2031-11-29",{"name":464,"class":45},{"id":556,"slug":557,"hasResults":11,"nctId":558,"briefTitle":559,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":11,"sex":15,"minAge":562,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":565,"conditions":566,"keywords":567,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":46},"100482734","search-for-bio-diagnostic-and-prognostic-markers-in-adult-vascularitis-100482734","NCT05565885","Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis","BIOVAS","Inclusion Criteria:\n\n* Age \\> 16 years\n* Active vasculitis, new diagnosis or relapse\n* IgA vasculitis\n* ANCA vasculitis\n* Giant cell arteritis\n\nExclusion Criteria:\n\n* Person who has objected to the processing of data\n* Pregnant woman\n* Patient positive for HIV, HBV, HCV\n* Treatment in the previous month with corticosteroids, immunosuppressive drugs or biotherapy.\n* Patient unable to understand the information leaflet\n* Adult under guardianship or curatorship","16 Years",{"count":564,"type":19},225,"To date, there are no reliable diagnostic blood markers of adult vasculitis. To date, the diagnosis of vasculitis is based on invasive procedure, biopsy of affected tissues potentially at risk of complication . In addition, there are no reliable biomarkers to predict the evolution of vasculitis (relapse, refractory form ...) necessary for the management of patients (type of treatment, duration ..)\n\nProspective study, monocentric (CHU de Tours), non-interventional, aimed at finding diagnostic and prognostic biomarkers (both metabolomic and immunologic) in adult vasculitis patients.",[25],[568,569,570],"biomarkers","diagnosis","prognosis","2025-05-22",{"date":573,"type":38},"2025-05-29",{"date":575,"type":38},"2022-11-22",{"date":577,"type":19},"2037-12",{"name":579,"class":45},"University Hospital, Tours",{"id":581,"slug":582,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":46},"100576016","characterization-of-bamboo-and-other-vocal-cord-lesions-responsible-for-dysphonia-in-patients-with-systemic-autoimmune-diseases-bamboo-100576016","NCT06779799","Characterization of \"Bamboo\" and Other Vocal Cord Lesions Responsible for Dysphonia in Patients With Systemic Autoimmune Diseases (BAMBOO)","Characterization of \"Bamboo\" and Other Vocal Cord Lesions Responsible for Dysphonia in Patients With Systemic Autoimmune Diseases.","BAMBOO","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* With a systemic autoimmune disease : rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, primary Sjogren disease, sarcoidosis, vasculitis, myositis, Still disease, Sharp syndrome.\n* Suffering from dysphonia.\n* With a cord vocal\u002Flaryngeal lesion highlighted.\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Dysphonia due to a cord vocal palsy related to a neurological condition or malignancy\n* History of cervical radiation\n* History of oro-tracheal intubation\n* Laryngeal cancer\n* Participation deny\n* Impossibility of consent\n* Patients with legal protection",{"count":589,"type":19},150,"The goal of this multicenter retrospective observational study is to provide an inventory of the specific and non specific cord vocal lesions that can cause dysphonia in patients with systemic autoimmune diseases. The main question it aims to answer is:\n\n* What are the main cord vocal lesions responsible for dysphonia in patients with a systemic autoimmune disease?\n* Is there a diagnosis delay regarding those lesions?\n* How are those lesions managed? Participants suffering from dysphonia in a context of a systemic autoimmune disease will be identified, with a review of their medical record.",[592,593,25],"Dysphonia","Connective Tissue Disease","2025-01-13",{"date":596,"type":38},"2025-01-17",{"date":598,"type":38},"2024-12-01",{"date":600,"type":19},"2025-05-31",{"name":602,"class":45},"University Hospital, Brest",{"id":604,"slug":605,"hasResults":11,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":58,"phases":613,"briefSummary":614,"conditions":615,"keywords":617,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":57},"100410794","phase-2-efficacy-and-safety-of-belimumab-in-the-treatment-of-non-infectious-active-cryoglobulinemia-vasculitis-compared-to-placebo-tribeca-study-treatment-nd-belimumab-in-cryoglobulinemia-associated-vasculitis-100410794","NCT04629144","Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)","Multicenter Randomized Double-blind Study Comparing the Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)","TRIBECA","Inclusion Criteria:\n\nThe eligibility criteria will be checked at the inclusion\u002Frandomization visit. Patients meeting the following criteria may be included in the study:\n\n1. Age \\> 18 years\n2. Written inform consent\n3. Active mixed cryoglobulinemia vasculitis, at initiation of rituximab, define by a. a clinically active vasculitis with skin, joint, renal, peripheral nerve, central neurological, digestive, pulmonary and\u002For cardiac involvement , b. history of positive cryoglobulinemia and\u002For positive Rheumatoid factor associated with low C4 complement level , and\u002For a monoclonal component (IgM Kappa) and\u002For a histologal proof of vasculitis in the affected organs\n4. Affiliated to National French social security system\n5. Having received Rituximab as induction therapy within 6 weeks (1 to 4 infusions, dose at the discretion of the investigator)\n6. Female subjects of childbearing potential must have a negative serum or urinary pregnancy test at inclusion visit, and confirmed monthly while in study, out to at least 92 days (5 half lives) post last dose.\n7. For subjects with reproductive potential (male or female), a willingness to use contraceptive measures adequate to prevent the subject or the subject's partner from becoming pregnant during the study from 2 weeks prior to administration of the 1st dose of study agent until 92 days after the last dose of study agent. Therefore the subjects agree to 1 of the following:\n\n   1. Complete abstinence from intercourse from 2 weeks prior to administration of the 1st dose of study agent until 92 days after the last dose of study agent (Sexual inactivity by abstinence must be consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception) OR\n   2. Consistent and correct use of 1 of the following acceptable methods of birth control for 1 month prior to the start of the study agent, during the study, and 92 days after the last dose of study agent o Oral contraceptive, either combined or progestogen alone o Injectable progestogen o Implants of levonorgestrel or etonogestrel o Estrogenic vaginal ring o Percutaneous contraceptive patches o Intrauterine device (IUD) or intrauterine system (IUS) with \\\u003C1% failure rate as stated in the product label\n\n      o Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, \"documented\" refers to the outcome of the investigator's\u002Fdesignee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records\n      * Double barrier method: condom and occlusive cap (diaphragm or cervical\u002Fvault caps) plus spermicidal agent (foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository) These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring subjects understand how to properly use these methods of contraception.\n8. HIV negative serology ; negative HBs Ag test and HBc Ab test; HCV negative serology or negative HCV RNA if positive HCV serology within 3 months before inclusion:\n\n   o In case of negative AgHBs and positive HBc Ab test, HBV DNA test must be negative; AND Hepatitis B surveillance should be started (monthly HBsAg and HBV DNA testing for the duration of the study treatment and at least every 12 weeks after treatment is discontinued for the duration of study treatment. In addition, antiviral prophylaxis should be started before the first administration of the study treatment and continued until 12 months after completion of study treatment; HCV negative serology or negative HCV RNA if positive HCV serology within 3 months before inclusion\n9. neutrophils (ANC) \\>1x109\u002FL\n\nExclusion criteria :\n\nSubjects will be not included from the study if they meet any of the following criteria:\n\n1. Patient with a vasculitis unrelated to cryoglobulinemia\n2. Patient with non active cryoglobulinemia vasculitis, at initiation of rituximab. Patients with mixed inactive vasculitis following rituximab administration may be included.\n3. Excluded concomitant medications:\n\n   1. 365 days Prior to Investigational Medicinal Product (Belimumab or placebo):: Any biologic investigational agent (e.g., abetimus sodium, anti CD40L antibody, BG9588\u002F IDEC 131) Investigational agent applies to any drug not approved for sale in the country in which it is being used\n   2. 180 Days Prior to Investigational Medicinal Product (Belimumab or placebo):: Intravenous cyclophosphamide\n   3. 30 Days Prior to Investigational Medicinal Product (Belimumab or placebo): (or 5 half lives, whichever is greater) Any non-biologic investigational agent Investigational agent applies to any drug not approved for sale in the country in which it is being use\n   4. Live vaccines within 30 days prior to baseline or concurrently with Investigational Medicinal Product (Belimumab or placebo)\n4. Have a history of malignant neoplasm within the last 5 years, other than carcinoma in situ of the cervix or excised basal cell, squamous cell carcinoma of the skin and low grade hemopathy with no indication for a specific treatment\n5. Have evidence of serious suicide risk including any history of suicidal behaviour in the last 6 months and\u002For any suicidal ideation in the last 2 months or who in the investigator's judgment, pose a significant suicide risk\n6. Have a Progressive multifocal leukoencephalopathy\n7. Have a history of a primary immunodeficiency\n\n9\\. Have a history of major organ transplant or hematopoietic stem cell\u002Fmarrow transplant or renal transplant\n\n10\\. Infection history:\n\n* Currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus\n* Infection requiring hospitalization and\u002For use of parenteral (IV or IM) antibiotics (antibacterials, antivirals, anti-fungals, or anti-parasitic agents) within 60 days of the inclusion visit.\n\n  11\\. Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 365 days prior to the inclusion visit\n\n  12\\. Have a historically positive HIV test according to results obtained within 3 months prior to inclusion visit\n\n  13\\. Hepatitis status according to results obtained within 3 month prior to inclusion visit :\n* Positive test for hepatitis B RNA\n* Positive test for Hepatitis C RNA\n\n  14\\. Have a history of a hypersensitivity or an anaphylactic reaction to parenteral administration of Belimumab, corticosteroids or any excipients of the treatments administered during the study\n\n  15\\. If Women of Child Bearing Potential (WCBP) are included please see special instructions in Inclusion criteria\n\n  16\\. Pregnant or breast feeding women\n\n  17\\. Have any intercurrent significant medical or psychiatric illness that the investigator considers would make the candidate unsuitable for the study\n\n  18\\. Patients under legal protection or unable to consent\n\n  19\\. Participation to another interventional study",{"count":612,"type":19},48,[87],"Cryoglobulinemia vasculitis (CV) is a systemic immune-mediated small vessel vasculitis. Rituximab proved effective on main vasculitis signs, with a complete clinical response of 65%. However, CV relapse is noted in up to 40% of patients. Following rituximab, serum Blys concentration significantly increased and may favor relapses. Tribeca is a multicentre randomized controled study comparing safety and efficacy of belimumab to placebo in non infectious cryoglobulinemia vasculitis.",[25,616],"Cryoglobulinemia",[618,25,616,619],"Belimumab","Non-infectious","2024-06-24",{"date":622,"type":38},"2024-06-26",{"date":624,"type":38},"2021-10-20",{"date":626,"type":19},"2025-10-20",{"name":464,"class":45},{"id":629,"slug":630,"hasResults":11,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":634,"eligibilityCriteria":635,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":636,"targetDuration":638,"studyType":21,"phases":4,"briefSummary":639,"conditions":640,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":722,"lastUpdatePostDateStruct":723,"startDateStruct":725,"completionDateStruct":727,"leadSponsor":729,"locationsCount":46},"100521150","national-registry-of-rare-kidney-diseases-100521150","NCT06065852","National Registry of Rare Kidney Diseases","National Registry of Rare Kidney Diseases (RaDaR)","RaDaR","* Kidney Rare Disease\n* Paeds and adults\n* Eligibility differs for each rare disease group\n* See: https:\u002F\u002Fukkidney.org\u002Frare-renal\u002Frecruitment",{"count":637,"type":19},35000,"30 Years","The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.\n\nThe purpose of this research is to:\n\n* Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition.\n* Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better.\n* Further the development of future treatments.\n\nParticipants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.",[641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,486,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,369,677,678,679,680,681,682,683,684,685,686,687,688,689,690,691,692,693,694,695,696,697,698,699,700,701,702,703,704,705,706,707,708,709,710,711,712,713,714,715,716,717,718,719,720,721,25],"Adenine Phosphoribosyltransferase Deficiency","AH Amyloidosis","AHL Amyloidosis","AL Amyloidosis","Alport Syndrome","Atypical Hemolytic Uremic Syndrome","Autoimmune Distal Renal Tubular Acidosis","Autosomal Recessive Proximal Renal Tubular Acidosis","Autosomal Recessive Distal Renal Tubular Acidosis","Autosomal Dominant Polycystic Kidney Disease","Autosomal Recessive Polycystic Kidney Disease","Bartter Syndrome","BK Nephropathy","C3 Glomerulopathy With Monoclonal Gammopathy","C3 Glomerulopathy","Crystalglobulinaemia","Crystal-storing Histiocytosis","Cystinosis","Cystinuria","Dense Deposit Disease","Dent Disease","Denys-Drash Syndrome","Dominant Hypophosphataemia With Nephrolithiasis and\u002For Osteoporosis","Drug Induced Fanconi Syndrome","Drug-Induced Hypomagnesemia","Drug-Induced Nephrogenic Diabetes Insipidus","Epilepsy, Ataxia, Sensorineural Deafness and Tubulopathy","Fabry Disease","Familial Hypomagnesemia With Hypercalciuria and Nephrocalcinosis","Familial Primary Hypomagnesemia With Hypocalcuria","Familial Primary Hypomagnesaemia With Normocalciuria","Familial Renal Glucosuria","Fanconi Renotubular Syndrome 1","Fanconi Renotubular Syndrome 2","Fanconi Renotubular Syndrome 3","Fibrillary Glomerulonephritis","Focal Segmental Glomerulosclerosis","Generalised Pseudohypoaldosteronism Type 1","Gitelman Syndrome","Heavy-Metal-Induced Fanconi Syndrome","Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes","Hereditary Renal Hypouricemia","Hereditary Hypophosphatemic Rickets With Hypercalciuria","Hyperuricaemic Nephropathy","IgA Nephropathy","Immunotactoid Glomerulonephritis With Organised Microtubular Mononoclonal Immunoglobulin Deposits","Inherited Renal Cancer Syndromes","Intracapillary Monoclonal IgM Without Cryoglobulin","Intraglomerular\u002FCapillary Lymphoma\u002FLeukaemia","Isolated Autosomal Dominant Hypomagnesaemia Glaudemans Type","Liddle Syndrome","Light Chain Cast Nephropathy","Light Chain Proximal Tubulopathy Without Crystals","Light Chain Proximal Tubulopathy With Crystals","Lowe Syndrome","Membranous Nephropathy","Membranoproliferative Glomerulonephritis","Medullary Cystic Kidney Disease","Minimal Change Nephropathy","Mitochondrial Disease Of The Kidney","Monoclonal Immunoglobulin Deposition Disease","Nail Patella Syndrome","Nephrogenic Diabetes Insipidus","Nephrogenic Syndrome of Inappropriate Antidiuresis","Nephronophthisis","Primary Hypomagnesemia With Secondary Hypocalcemia","Primary Hyperoxaluria","Proliferative Glomerulonephritis With Monoclonal IgG Deposits","Proximal Tubulopathy Without Crystals","Pseudohypoaldosteronism Type 1, 2A-2E","Pure Red Cell Aplasia","Retroperitoneal Fibrosis","Sickle Cell Nephropathy","Shiga Toxin Associated Haemolytic Uraemic Syndrome","Steroid Resistant Nephrotic Syndrome","Steroid-Sensitive Nephrotic Syndrome","Thin Basement Membrane Nephropathy","Thrombotic Microangiopathy With Monoclonal Gammopathy","Type 1 Cryoglobulinaemic Glomerulonephritis","Tuberous Sclerosis","Unclassified Monoclonal Gammopathy Of Renal Significance","2023-09-26",{"date":724,"type":38},"2023-10-04",{"date":726,"type":38},"2009-11-06",{"date":728,"type":19},"2039-12-31",{"name":730,"class":45},"UK Kidney Association",{"id":732,"slug":733,"hasResults":11,"nctId":734,"briefTitle":735,"officialTitle":736,"acronym":737,"eligibilityCriteria":738,"healthyVolunteers":417,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":739,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":740,"conditions":741,"keywords":742,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":743,"lastUpdatePostDateStruct":744,"startDateStruct":746,"completionDateStruct":748,"leadSponsor":750,"locationsCount":46},"100363001","whole-exome-sequencing-of-familial-and-pediatric-forms-of-vasculitis-100363001","NCT04006535","Whole Exome Sequencing of Familial and Pediatric Forms of Vasculitis","Identification of Susceptibility Loci and Genes for Systemic Vasculitis Risk, by Analyzing Whole Exome Sequencing of Familial and Pediatric Forms of Vasculitis (FAMILYVASC Study)","FAMILYVASC","Inclusion criteria for subjects with vasculitis\n\n* Children and adults\n* Patients with vasculitis, as defined in the Chapel Hill International Classification in its revised version of 2012\n* Patient information and signed informed consent\n* Pregnant and breastfeeding women can be included in the study\n\nInclusion criteria for healthy subjects\n\n* Children and adults\n* Do not have vasculitis, as defined in the Chapel Hill International Classification in its revised version of 2012, or relatives on the 1st; 2nd; 3rd or 4th degree of a patient with vasculitis\n* Patient information and signed informed consent\n* Pregnant and breastfeeding women can be included in the study\n\nExclusion criteria:\n\n* Refusal of consent or inability to obtain consent\n* Dementia or unauthorized patient, for psychiatric or intellectual failure reasons, to receive information about the protocol and to give informed consent.\n* Uncooperative patient, or any pathology that could make the patient potentially non-compliant to the study procedures, and patients interned for regulatory or legal reasons.",{"count":131,"type":19},"The FAMILYVASC study is a prospective observational study which will aim to identify susceptibility loci and genes for systemic vasculitis risk in patients with familial or pediatric forms of vasculitis. Genetic analysis based on whole exome sequencing will be carried out through salivary DNA.",[25],[25],"2019-07-03",{"date":745,"type":38},"2019-07-08",{"date":747,"type":38},"2019-06-01",{"date":749,"type":19},"2029-06-01",{"name":751,"class":45},"Benjamin Terrier"]